The elusive nature of intrinsic efficacy

Trends in Pharmacological Sciences

Volumn 19, Issue 7, 1998, Pages 270-276

  Clarke, William P ^a   Bond, Richard A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; REVIEW;

EID: 0032127619     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(97)01138-3     Document Type: Review

References (29)

1. 1 Clark, A. J. (1937) in Heffter's Handbuch der. Experimentellen Pharmakologie (Vol. 4), Springer-Verlag
2. 2 Ariëns, E. J. (1954) Arch. Int. Pharmacodyn. Ther. 99, 32-49
3. 3 Stephenson, R. P. (1956) Br. J. Pharmacol. 11, 379-393
4. 4 Furchgott, R. F. (1966) in Advances in Drug Research (Vol. 3) (Harper, N. J. and Simmonds, A. B., eds), pp. 21-55, Academic Press
5. 5 MacKay, D. (1966) J. Pharm. Pharmacol. 18, 201-222
6. 6 MacKay, D. (1988) Trends Pharmacol Sci. 9, 156-157
7. 7 Leff, P. and Harper, D. (1989) J. Theor. Biol. 140, 381-397
8. 8 Kenakin, T. P. (1988) Life Sci. 43, 1095-1101
9. 9 Milligan, G., Bond, R. A. and Lee, M. (1995) Trends Pharmacol. Sci. 16, 10-13
10. 10 Monod, J., Wyman, J. and Changeux, J. P. (1965) J. Biol. Chem. 12, 88-118
11. 11 Leff, P. (1995) Trends Pharmacol. Sci. 16, 89-97
12. 12 Bond, R. A. et al. (1995) Nature 374, 272-276
13. 13 Kenakin, T. P. (1996) Trends Pharmacol. Sci. 17, 190-191
14. 14 Burgen, A. S. V. (1981) Fed. Proc. 40, 2723-2728
15. 15 Spengler, D. et al. (1993) Nature 365, 170-175
16. 16 Robb, S. et al. (1994) EMBO J. 13, 1325-1330
17. 17 Berg, K. A. et al. Mol. Pharmacol. (in press)
18. 18 Kenakin, T. (1995) Trends Pharmacol. Sci. 16, 232-238
19. 19 Kenakin, T. (1996) Pharmacol. Rev. 48, 413-463
20. 20 Leff, P., Scaramellini, C., Law, C. and McKechnie, K. (1997) Trends Pharmacol. Sci. 18, 355-362
21. 21 Ehlert, F. J. (1985) Mol. Pharmacol. 28, 410-421
22. 22 Costa, T., Ogino, Y., Munson, P. J., Onaran, H. O. and Rodbard, D. (1992) Mol. Pharmacol. 41, 549-560
23. 23 Kent, R. S., De Lean, A. and Lefkowitz, R. J. (1980) Mol. Pharmacol. 17, 14-23
24. 24 Gether, U., Lin, S. and Kobilka, B. K. (1995) J. Biol. Chem. 270, 28268-28275
25. 25 Kenakin, T. (1997) in Pharmacologic Analysis of Drug-Receptor Interaction (3rd edn), pp. 289-330, Lippincott-Raven Publishers
26. 26 Milligan, G. and Bond, R. A. (1997) Trends Pharmacol. Sci. 18, 468-474
27. 27 Chidiac, P., Nouet, S. and Bouvier, M. (1996) Mol. Pharmacol. 50, 662-669
28. 28 Berg, K. A., Maayani, S. and Clarke, W. P. (1996) Mol. Pharmacol. 50, 1017-1023
29. 29 Berg, K. A., Clarke, W. P., Sailstad, C., Saltzman, A. and Maayani, S. (1994) Mol. Pharmacol. 46, 477-485